

1 --16. The agent of claim 12 wherein said LBP comprises hybrid proteins of LBP
2 with the LPS binding site of the bactericidal/permeability increasing protein (BPI)
3 or LBP with the LPS binding site of the limulus anti-LPS factor (LALF).--

Q1 1 --17. The agent of claim 12 containing point-mutated variants the functions of
2 which are improved at the LPS binding site (amino acids 91-101) by individual
3 exchanges of amino acids.--

1 --18. A process for producing the agent of claim 12, which comprises express-
2 ing LBP in the baculovirus and in CHO cells, first of all, as fusion protein, and then
3 purifying by separating by the participant in the fusion.--

1 --19. A process for treating septicemia caused by gram-negative bacteria which
2 comprises administering to a patient in need therefor the agent of claim 12.--

1 --20. The process of claim 19, wherein the septicemia is caused by gram-
2 positive bacteria.--

1 --21. A process for treating systemic inflammatory response syndrome caused
2 by trauma and injury, in need therefor the agent of claim 12.--

1 --22. A process for obtaining the agent of claim 12, which comprises cloning
2 the LBP gene in an adenoviral vector behind a strong promoter and transferring the
3 gene into the affected liver cells.--